Financing Biomedical Innovation

Estimates of Probabilities of Successful Development of Pain Medications: An Analysis of Pharmaceutical Clinical Development Programs 2000-2020

(2022) Dermot P. Maher et al.   ANESTHESIOLOGY

Find and Replace: R&D Investment Following the Erosion of Existing Products

(2022) Joshua L. Krieger et al.   MANAGEMENT SCIENCE

Differentiated dollars

(2022) Daniel L. Alvarez et al.   NATURE BIOTECHNOLOGY

Financing Health Care Delivery

(2022) Jonathan Gruber   Annual Review of Financial Economics

Incorporating Patient Preferences via Bayesian Decision Analysis

(2021) Shomesh E. Chaudhuri et al.   Clinical Journal of the American Society of Nephrology

Trials and Terminations: Learning from Competitors’ R&D Failures

(2021) Joshua L. Krieger   MANAGEMENT SCIENCE

Life sciences intellectual property licensing at the Massachusetts Institute of Technology

(2021) Samuel Huang et al.   NATURE BIOTECHNOLOGY

Accelerating glioblastoma therapeutics via venture philanthropy

(2021) Kien Wei Siah et al.   DRUG DISCOVERY TODAY

IPO peer effects

(2021) Cyrus Aghamolla et al.   JOURNAL OF FINANCIAL ECONOMICS

Do Mandatory Disclosure Requirements for Private Firms Increase the Propensity of Going Public?

(2021) CYRUS AGHAMOLLA et al.   JOURNAL OF ACCOUNTING RESEARCH

Hospital Financial Health and Clinical Choices: Evidence from the Financial Crisis

(2021) Manuel Adelino et al.   MANAGEMENT SCIENCE

Rushed Innovation: Evidence from Drug Licensing

(2020) Manuel Hermosilla   MANAGEMENT SCIENCE

Breaking Eroom’s Law

(2020) Michael S. Ringel et al.   NATURE REVIEWS DRUG DISCOVERY

A cost/benefit analysis of clinical trial designs for COVID-19 vaccine candidates

(2020) Donald A. Berry et al.   PLoS One

Patents, Data Exclusivity, and the Development of New Drugs

(2020) Fabian Gaessler et al.   REVIEW OF ECONOMICS AND STATISTICS

Acceleration of rare disease therapeutic development: a case study of AGIL-AADC

(2019) Sonya Das et al.   DRUG DISCOVERY TODAY

Is the FDA too conservative or too aggressive?: A Bayesian decision analysis of clinical trial design

(2019) Leah Isakov et al.   JOURNAL OF ECONOMETRICS

Adaptive platform trials: definition, design, conduct and reporting considerations

(2019)   NATURE REVIEWS DRUG DISCOVERY

Estimation of clinical trial success rates and related parameters

(2018) Chi Heem Wong et al.   BIOSTATISTICS

Patient-centered clinical trials

(2018) Shomesh E. Chaudhuri et al.   DRUG DISCOVERY TODAY

Product competition, managerial discretion, and manufacturing recalls in the U.S. pharmaceutical industry

(2018) George P. Ball et al.   JOURNAL OF OPERATIONS MANAGEMENT

New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics

(2018) Sonya Das et al.   JAMA Oncology

Patents as collateral for securitization

(2017) Nishad Deshpande et al.   NATURE BIOTECHNOLOGY

Just how good an investment is the biopharmaceutical sector?

(2017) Richard T Thakor et al.   NATURE BIOTECHNOLOGY

Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology

(2017) Vahid Montazerhodjat et al.   JAMA Oncology

Financing drug discovery via dynamic leverage

(2016) Vahid Montazerhodjat et al.   DRUG DISCOVERY TODAY

Innovation in the pharmaceutical industry: New estimates of R&D costs

(2016) Joseph A. DiMasi et al.   JOURNAL OF HEALTH ECONOMICS

Estimating the biotech sector's contribution to the US economy

(2016) Robert Carlson   NATURE BIOTECHNOLOGY

Capitalizing on convergence for health care

(2016) P. Sharp et al.   SCIENCE

Buying cures versus renting health: Financing health care with consumer loans

(2016) Vahid Montazerhodjat et al.   Science Translational Medicine

Cancer megafunds with in silico and in vitro validation: accelerating cancer drug discovery via financial engineering without financial crisis

(2016) Xianjin Yang et al.   Oncotarget

Health, Wealth, and the 21st Century Cures Act

(2016) Andrew W. Lo et al.   JAMA Oncology

A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds

(2015) JA DiMasi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Financing translation: Analysis of the NCATS rare-diseases portfolio

(2015) David E. Fagnan et al.   Science Translational Medicine

Predicting success in regulatory approval from Phase I results

(2014) Laeeq Malik et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

Parallel Discovery of Alzheimer's Therapeutics

(2014) A. W. Lo et al.   Science Translational Medicine

Financing drug discovery for orphan diseases

(2013) David E. Fagnan et al.   DRUG DISCOVERY TODAY

Survey of Oncologists about Shortages of Cancer Drugs

(2013) Keerthi Gogineni et al.   NEW ENGLAND JOURNAL OF MEDICINE

Commercializing biomedical research through securitization techniques

(2012) Jose-Maria Fernandez et al.   NATURE BIOTECHNOLOGY

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs

(2010) J A DiMasi et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III

(2008) Robert H. El-Maraghi et al.   JOURNAL OF CLINICAL ONCOLOGY